Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY – Get Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 103,355 shares traded hands during mid-day trading, an increase of 244% from the previous session’s volume of 30,032 shares.The stock last traded at $70.48 and had previously closed at $70.46.
Analysts Set New Price Targets
A number of brokerages have issued reports on SDZNY. Jefferies Financial Group cut shares of Sandoz Group from a “strong-buy” rating to a “hold” rating in a report on Friday, August 8th. Barclays raised Sandoz Group to a “strong-buy” rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Sandoz Group has a consensus rating of “Moderate Buy”.
Read Our Latest Report on Sandoz Group
Sandoz Group Stock Down 1.4%
About Sandoz Group
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Featured Stories
- Five stocks we like better than Sandoz Group
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
- Basic Materials Stocks Investing
- Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Strong Quarter, Weak Reaction: Why GitLab Shares Dropped
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
